Development potential of rifalazil

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 255-271

  Rothstein, David M ^a   Hartman, Arthur D ^b   Cynamon, Michael H ^c   Eisenstein, Barry I ^a  

^a ActivBiotics Inc   (United States)

^b Hartman Medical Communications Inc   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Antibiotic associated colitis; Atherosclerosis; Chlamydia; Gastric ulcer disease; Rifalazil; Rifampin; Tuberculosis

Indexed keywords

ABI 1657; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; CEFAZOLIN; CHOLESTEROL; CLINDAMYCIN; CLOSTRIDIUM TOXIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DRUG METABOLITE; ETHAMBUTOL; FLUCONAZOLE; ISONIAZID; KETOCONAZOLE; METICILLIN; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RNA POLYMERASE; STEROID; TROLEANDOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; CELL LEVEL; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG STRUCTURE; HELICOBACTER PYLORI; HUMAN; LUNG TUBERCULOSIS; NONHUMAN; NONSPECIFIC URETHRITIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; SOFT TISSUE INFECTION; STOMACH ULCER; TOXIN SYNTHESIS; UTERINE CERVICITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037315218     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.255     Document Type: Review

References (144)

1. FUJII K, SAITO H, TOMIOKA H et al.: Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob. Agents Chemother. (1995) 39:1489-1492.
2. MORSE R, O'HANLON K, COLLINS MD: Phylogenetic, amino acid content and indel analyses of the beta subunit of DNA-dependent RNA polymerase of Gram-positive and Gram-negative bacteria. Int. J. Syst. Evol. Microbiol. (2002) 52(Pt 5):1477-1484.
3. CAMPBELL EA, KORZHEVA N, MUSTAEV A et al.: Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell (2001) 104:901-912.
4. KAPUR V, LI LL, HAMRICK MR et al.: Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch. Pathol. Lab. Med. (1995) 119:131-138.
5. MUSSER JM: Antimicrobial agent resistance in mycobacteria; molecular genetic insights. Clin. Microbiol. Rev. (1995) 8:496-514.
6. MOGHAZEH SL, PAND X, ARAIN T et al.: Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. (1996) 40:2655-2657.
7. HEEP M, RIEGER U, BECK D et al.: Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2000) 44:1075-1077.
8. QIAN L, ABE C, LIN TP et al.: rpoB Genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J. Clin. Microbiol. (2002) 40:1091-1094.
9. WILLIAMS DL, SPRING L, COLLINS L et al.: Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1998) 42:1853-1857.
10. DHOPLE AM, DHOPLE AA, IBANEZ MA: Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents (1997) 8:209-214.
11. YANG B, KOGA H, OHNO H et al.: Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. (1998) 42:621-628.
12. PARK YK, KIM BJ, RYU et al.: Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. (2002) 6:166-170.
13. FUJII K, TSUJI A, MIYAZAKI S et al.: In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob. Agents Chemother. (1994) 38:1118-1122.
14. STAMM WE, GEISLER WM, SUCHLAND RJ: Assessment of antimicrobial resistance in Chlamydia trachomatis strains associated with treatment failure or same strain recurrence. Chlamydial Infect.: Proc. 105th Int. Symp. Hum. Chlamydial Infect., Antalya, Turkey. (2002):353-360.
15. AKADA JK, SHIRAI M, FUJII K et al.: In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob. Agents Chemother. (1999) 43:1072-1076.
16. SAITO, H, TOMIOKA H, SATO K et al.: In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob. Agents Chemother. (1991) 35:542-547.
17. LUNA-HERRERA J, REDDY MV, GANGADHARAM PR: In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob. Agents Chemother. (1995) 39:440-444.
18. LANCINI G, PALLANZA R, SILVESTRI LG: Relationships between bactericidal effect and inhibition of ribonucleic acid nucleotidyltransferase by rifampicin in Escherichia coli K-12. J. Bacteriol. (1969) 97:761-768.
19. HOSOE H, MAE T. KONISHI E et al.: Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob. Agents Chemother. (1996) 40(12):2749-2755.
20. MAE T, KONISHI E, HOSOE K, HIDAKA T: Isolation and identification of major metabolites of rifalazil in mouse and human. Xenobiotica (1999) 29:1073-1087.
21. ROSE LM, VASILJEV KM, ADAMS P et al.: Safety and pharmacokinetics of PA-1648 a new rifamycin in normal volunteers. Am. J. Rispir. Crit. Care Med. (1999) 159(Suppl.):A495.
22. HOSOE K, MAE T, YAMASHITA K et al.: Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica (1995) 26:321-332.
23. PIDDOCK LJV, RICCI V: Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis. J. Antimicrob Chemother. (2000) 45:681-684.
24. MAE T, HOSOE K, YAMAMOTO T, HIDAKA T et al.: Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica (1998) 28:759-766.
25. FINCH CK, CHRISMAN CR, BACIEWICZ AM et al.: Rifampin and rifabutin drug interactions. Arch. Intern. Med. (2002) 162:985-992.
26. INABA T, FISCHER NE, RIDDICK DS et al.: HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. (1997) 93:215-219.
27. MAE T, INABA T, KONISHI E et al.: Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica (2000) 30(6):565-574.
28. ESPINAL MA, LAZLO A, SIMONSEN L et al.: Global trends in resistance to antituberculosis drugs. World Health Organization-international union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N. Engl. J. Med. (2001) 344:1294-1303.
29. DYE C: WHO, unpublished data. Cited in: Economics of TB Drug Development (2001):14.
30. KUZE F: Antimycobacterial activities of rifamycin derivatives. Kekkaku (1991) 66:679-685.
31. YAMANE T. HASHIZUME T, YAMASHITA K et al.: Synthesis and biological activity of 3′-hydroxy-5′-minobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. (Tokyo) (1993) 41:148-155.
32. HIRATA T, SAITO H, TOMIOKA H et al.: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1995) 39:2295-2303.
33. YAMAMOTO T, AMITANI R, SUZUKI K et al.: In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1996) 40:426-428.
34. SATO K, TOMIOKA H, SAITO H et al.: In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Kekkaku (1996) 71:459-464.
35. TOMIOKA H, SAITO H, FUJII K et al.: In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrob. Agents Chemother. (1993) 37:67-70.
36. SAITO H, TOMIOKA H, SATO K et al.: Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice. Int. J. Lepr. Other Mycobact. Dis. (1994) 62:43-47.
37. DHOPLE AM, IBANEZ MA: The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J. Antimicrob. Chemother. (1995) 35:463-471.
38. DHOPLE AM, IBANEZ MA: In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Antimicrob. Agents Chemother. (1995) 39:2116-2119.
39. DHOPLE AM: In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648. Arzneimittelforschung (2001) 51:501-505.
40. DHOPLE AM: In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans. Int. J. Antimicrob. Agents (2001) 17:57-61.
41. KUZE F, YAMAMOTO T, AMITANI R et al.: In vivo activities of new rifamycin derivatives against mycobacteria. Kekkaku (1991) 66:7-12.
42. REDDY MV, LUNA-HERRERA J, DANELUZZI D et al.: Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tuber. Lung Dis. (1996) 77:154-159.
43. DOI N: Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model. Kekkaku (1998) 73:53-64.
44. KLEMENS SP, GROSSI MA, CYNAMON MH: Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1994) 10:2245-2248.
45. KELLY BP, FURNEY SK, JESSEN MT et al.: Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother (1996) 40:2809-2812.
46. KLEMENS SP, CYNAMON MH: Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1996) 40:298-301.
47. GIDOH M, TSUTSUMI S, YAMANE T et al.: Bactericidal action at low doses of a new rifamycin derivative, 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) on Mycobacterium leprae inoculated into footpads of nude mice. Lepr. Rev. (1992) 63:319-328.
48. LENAERTS AM, CHASE SE, CHMIELEWSKI AJ et al.: Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob. Agents Chemother. (1999) 43:2356-2360.
49. LENAERTS AM, CHASE SE, CYNAMON MH: Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. Antimicrob. Agents Chemother. (2000) 44:3167-3168.
50. SHOEN CM, DESTEFANO MS, CYNAMON MH: Durable cure for tuberculosis: Rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin. Infect. Dis. (2000) 30:S288-S290.
51. DIETZE R, TEIXEIRA L, ROCHA LM et al.: Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother (2001) 45:1972-1976.
52. HOECHST MARION ROUSSEL, Inc: Priftin (rifapentine) Advisory Panel Briefing Document (14 April 1998).
53. BENSON CA: Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. AIDS Clin. Rev. (1997-98):271-287.
54. TOMIOKA H, SAITO H: In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648. Int. J. Lepr. Other Mycobact. Dis. (1993) 61:255-258.
55. TOMIOKA H, SAITO H, SATO K et al.: Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother. (1992) 36:387-393.
56. EMORI M, SAITO H, SATO K et al.: Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob. Agents Chemother. (1993) 37:722-728.
57. BERMUDEZ LE, KOLONOSKI P, YOUNG LS et al.: Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob. Agents Chemother (1994) 38:1844-1848.
58. EMORI M, TOMIOKA H, SATO K et al.: Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection. Int. J. Antimicrob. Agents (1998) 10:59-65.
59. NIGHTINGALE SD, CAMERON DW, GORDIN FM et al.: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med. (1993) 329:828-833.
60. SWARZ MN: Cellulitis and subcutaneous tissue infections. In: Principles and Practice of Infectious Diseases (5th Ed.). GL Mandell, JE Bennett, R Dolin (Eds). Churchill Livingston, New York (2000):1037-1057.
61. VOSS A, MILATOVIC D, WALLRAUCH-SCHWARZ C et al.: Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13:50-55.
62. SCHMITZ FJ, KREY A, GEISEL R et al.: Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18:528-530.
63. AUBRY-DAMON H, SOUSSY CJ, COURVALIN P: Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. (1998) 42:2590-2594.
64. WICHELHAUS TA, SCHAFER V, BRADE V et al.: Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylocaccus aureus. Antimicrob. Agents Chemother. (1999) 43:2813-2816.
65. WICHELHAUS T, SCHAFER V, BRADE V et al.: Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylacoccus aureus. J. Antimicrob. Chemother. (2001) 47:153-156.
66. AUBRY-DAMON H, GALIMAND M, GERBAUD G et al.: rpoB mutation conferring rifampin resistance in Streptococcus pyogenes. Antimicrob. Agents Chemother. (2002) 46:1571-1573.
67. KIM OK, OHEMENG K, BARRETT JF: Advances in DNA gyrase inhibitors. Expert Opin. Investig. Drugs (2001) 10:199-212.
68. CRAIG WA, REDINGTON J, EBERT SC: Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. (1991) 27(Suppl. C):29-40.
69. ALARCON T, DOMINGO D, LOPEZ-BREA M: Antibiotic resistance problems with Helicobacter pylori. Int. J. Antimicrob. Agents (1999) 12:19-26.
70. MEGRAUD F: Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist. Updates (2001) 4:178-186.
71. GISBERT JP, PAJARES JM: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment. Pharmacol. Ther. (2002)16:1047-1057.
72. SUERBAUM S, MICHETTI P: Helicobacter pylori infection. N. Engl. J. Med. (2002) 347:1175-1186.
73. WALSH JH, PETERSON WL: The treatment of Helicobacter pylori infections in the management of peptic ulcer disease. N. Engl. J. Med. (1995) 333:984-991.
74. HEEP M, BECK D, BAYERDORFFER E et al.: Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob. Agents Chemother. (1999) 43:1497-1499.
75. HEEP M, ODENBREIT S, BECK D et al.: Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob. Agents Chemother. (2000) 44:1713-1715.
76. HEEP M, LEHN N, BRANDSTATTER B et al.: Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 21:143-145.
77. PERRI F, FESTA V, ANDRIULLI A: Treatment of antibiotic-resistant Helicobacter pylori. N. Engl. J. Med. (1998) 339:53.
78. GERRITS MM, DE ZOETE MR, ARENTS NL et al.: 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob. Agents Chemother. (2002) 46:2996-3000.
79. OSATO MS, REDDY R, REDDY SG et al.: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin. Arch. Intern. Med. (2001) 161:1217-1220.
80. ROCKEY DD, LENART J, STEPHENS RS: Genome sequencing and our understanding of Chlamydiae. Infect. Immun. (2000) 68(10):5473-5479.
81. EVERETT KDE: Chlamydia and Chlamydiales: More than meets the eye. Vet. Microbiol. (2000) 75:109-126.
82. WYRICK PB: Intracellular survival by Chlamydia. Cell. Microbiol. (2000) 2(4):275-282.
83. BAVOIL PM, HSIA R, OJCIUS DM: Closing in on Chlamydia and its intracellular bag of tricks. Microbiology (2000) 146:2723-2731.
84. WOLF K, FISCHER E, HACKSTADT T: Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells. Infect. Immun. (2000) 68(4):2379-2385.
85. BEATTY WL, MORRISON RP, BYRNE GI: Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. (1994) 58:686-699.
86. DRESES-WERRINGLOER U, PADUBRIN I, JURGENS-SAATHOFF B et al.: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. (2000) 44:3288-3297.
87. GERARD HC, FREISE J, WANG Z et al.: Chlamydia trachomatis genes whose products are related to energy metabolism are expressed differentially in active versus persistent infection. Microbes Infect. (2002) 4:13-22.
88. HAHN DL, AZENABOR AA, BEATTY WL et al.: Chlamydia pneumoniae as a respiratory pathogen. Front. Biosci. (2002) 7:e66-e76.
89. ASKIENAZY-ELBHAR M, SUCHET JH: Persistent 'silent' Chlamydia trachomatis female genital tract infections. Infect. Dis. Obstet. Gynecol. (1999) 7:31-34.
90. DEAN D, SUCHLAND RJ, STAMM WE: Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis. (2000) 182:909-916.
91. MALINVERNI R, KUO CC, CAMPBELL LA: Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J. Infect. Dis. (1995) 172:593-594.
92. LAITINEN K, LAURILA AL, LEINONEN M et al.: Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect. Immun. (1996) 64:1488-1490.
93. MORDHORST CH, WANG SP, GRAYSTON JT: Childhood trachoma in a nonendemic area. JAMA (1978) 239:1767-1771.
94. ROBLIN PM, REZNIK T, KUTLIN A et al.: In vitro activity of rifamycin derivatives ABI-1638 (rifalazil),ABI-1657, and ABI-1131 against recent clinical isolate of Chlamyidia pneumoniae. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002):232.
95. MAHONEY JB, SONG X: Antimicrobail activity of rifalazil for Chlamydia pneumoniae. 42nd Interscience Conference on Antimicrobial Agems and Chemotherapy San Diego, CA, USA (2002):165.
96. PAAVONEN J, EGGERT-KRUSE W: Chlamydia trachomatis: impact on human reproduction. Hum. Reprod. Update (1999) 5:433-447.
97. TURNER CF, ROGERS SM, MILLER HG et al.: Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 287:726-733.
98. SCHACTER J, GROSSMAN M, SWEET RL et al.: Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA (1986) 255:3374-3377.
99. PEARSON TA: New tools for coronary risk assessment: what are their advantages and limitations? Circulation (2002) 105:886-892.
100. BECKMAN JA, CREAGER MA, LIBBY P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 287:2570-2581.
101. CHENG A, BRAUNSTEIN JB, DENNISON C et al.: Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy Clin. Cardiol. (2002) 25:205-212.
102. PEARSON TA, BLAIR SN, DANIELS SR et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation (2002) 106:388-391.
103. HIATT WR: Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. (2002) 344:1608-1621.
104. LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation (2002) 105:1135-1143.
105. TAUBES G: Does inflammation cut to the heart of the matter? Science (2002) 296:242-245.
106. LUDEWIG B, ZINKERNAGEL RM, HENGARTNER H: Arterial inflammation and atherosclerosis. Trends Cardiovasc. Med. (2002) 12:154-159.
107. RIDKER PM, RIFAI N, ROSE L et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. (2002) 347:1557-1565.
108. ZEBRACK JS, ANDERSON JL: The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. Curr. Cardiol. Rep. (2002) 4:278-288.
109. FRISHMAN WH, ISMAIL AA: Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol. Rev. (2002) 10:199-210.
110. LEINONEN M, SAIKKU P: Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. (2002) 2:11-17.
111. SAIKKU P, LEINONEN M, MATTILA K et al.: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 2:983-986.
112. SAIKKU P: Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more. J. Infect. Dis. (2000) 181(Suppl. 3):S411-S413.
113. PAI J, KNOOP FC, HUNTER WJ 3rd et al.: Chlamydia pneumoniae and occlusive vascular disease: identification and characterization. J. Pharmacol. Toxicol. Methods (1998) 39:51-61.
114. KUO C, CAMPBELL LA. Detection of Chlamydia pneumoniae in arterial tissues. J. Infect. Dis. (2000) 181 (Suppl. 3):S432-S436.
115. TAYLOR-ROBINSON D, THOMAS BJ: Chlamydia pneumoniae in atherosclerotic tissue. J. Infect. Dis. (2000) 181(Suppl. 3):S437-S440.
116. SMIEJA M, MAHONY J, PETRICH A et al.: Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect. Dis. (2002) 2:21.
117. CAMPBELL LA, KUO CC: Chlamydia pneumoniae pathogenesis. J. Med. Microbiol. (2002) 51:623-625.
118. DUGAN JP, FEUGE RR, BURGESS DS: Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Clin. Ther. (2002) 24:719-735.
119. NGEH J, ANAND V, GUPTA S: Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin. Microbiol. Infect. (2002) 8:2-13.
120. BOMAN J, HAMMERSCHLAG MR: Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. (2002) 15:1-20.
121. MAHONY JB, COOMBES BK. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? FEMS Microbiol. Lett. (2001) 197:1-9.
122. CAMPBELL LA, MOAZED TC, KUO CC et al.: Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice. Clin. Microbiol. Infect. (1998) 4(Suppl. 4):S23-S32.
123. CAMPBELL LA, BLESSING E, ROSENFELD M et al.: Mouse models of C. pneumoniae infection and atherosclerosis. J. Infect. Dis. (2000) 181(Suppl. 3):S508-S513.
124. MUHLESTEIN JB, ANDERSON JL, HAMMOND EH et al.: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation (1998) 97:633-636.
125. FONG IW, CHIU B, VIIRA E et al.: Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? Clin. Diagn. Lab. Immunol. (1999) 6:891-894.
126. MUHLESTEIN JB: Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J. Infect. Dis. (2000) 181(Suppl. 3):S505-S507.
127. FONG IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J. Infect. Dis. (2000) 181(Suppl. 3):S514-S518.
128. PARCHURE N, ZOURIDAKIS EG, KASKI JC: Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation (2002) 105:1298-1303.
129. AMERICAN THORACIC SOCIETY AND CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. (2000) 161:S221-S247.
130. BARTLETT JG: Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. (2002) 346:334-339.
131. SAFDAR N, MAKI DG: The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med. (2002) 136:834-844.
132. MOYENUDDIN M, WILLIAMSON JC, OHL CA: Clostridium difficile-associated diarrhea: current strategies fbr diagnosis and therapy. Curr. Gastroenterol. Rep. (2002) 4:279-286.
133. MALNICK SD, ZIMHONYO: Treatment of Clostridium difficile-associated diarrhea. Ann. Pharmacother. (2002) 36:1767-1775.
134. HARBARTH S, COSGROVE S, CARMELI Y: Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob. Agents Chemother. (2002) 46:1619-1628.
135. EISENSTEIN BI, SCHAECHTER M: Normal microbial flora. In: Mechanisms of Microbial Disease (3rd Ed.). M Schaechter NC Engleberg, BI Eisenstein, G Medoff (Eds), Williams & Wilkins, Baltimore, USA (1998):11-17.
136. BARBUT F, RICHARD A, HAMADI K et al.: Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. (2000) 38:2386-2388.
137. ALONSO R, GROS S, PELAEZ T et al.: Molecular analysis of relapse versus reinfection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J. Hosp. Infect. (2001) 48:86-92.
138. ANTON PM, O'BRIEN M, EISENSTEIN B et al.: Rifalazil prevents and treates Clostridium difficile-associated infection in hamsters. Gastroenterology (2003) (In press).
139. MOELLERING RC Jr, CRAIG W, EDMOND M et al.: Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae. J. Chemother. (2002) 14(Suppl. 3):42-56.
140. FELMINGHAM D, REINERT RR, HIRAKATA Y et al.: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. (2002) 50(Suppl. S1):25-37.
141. DAVIDSON R, CAVALCANTI R, BRUNTON JL et al.: Resistance to Levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. (2002) 346:747-750.
142. ENRIGHT M, ZAWADSKI P, PICKERILL P et al.: Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb. Drug Resist. (1998) 4:65-70.
143. PADAYACHEE T, KLUGMAN KP: Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1999) 43:2361-2365.
144. VAN TILBURG PM, BOGAERT D, SLUIJTER M et al.: Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains. Clin. Infect. Dis. (2001) 33:e93-e96.